Joe Santangelo, COO, Inviragen Inc. Joined us at the World Vaccine Congress 2012 in Washington to give details on Inviragen's current vaccine pipeline. The current focus for the company is the development of vaccines for infectious diseases with a focus on emerging economies. With international operations with offices in Colorado, Wisconsin and Singapore, the vaccine pipeline currently has four key vaccines in development: vaccine for Dengue, EV71, Japanese Encephalitis and Chikungunya. Alongside these vaccines, research programs are currently operational for HPV, Avian and swine influenza, West Nile and Plague/ smallpox for biodefense.
This presentation focuses on the Dengue Vaccine. The ideal vaccine could be administered in one or two easy doses; it would be safe and encourage immunogenicity. In terms of distribution and use, thermal stability is required especially as the vaccine would be distributed across a wide area. A needle-free delivery option could also be beneficial.
DENVax is a DEN-2 PDK-53 ideal dengue vaccine backbone that may play a role in cellular immunity. Chimeras retain attenuating phenotypes and are immunogenic, whilst the tetravalent vaccine formulations are safe and generate neutralizing antibodies in preclinical models. It performed well in the phase 1 trials with encouraging preliminary safety and immunogenicity data.
Why not download the full presentation and discover more about:
Â· Generating long lasting immune response with the use of â€˜virus backbone'
Â· Manufacturing and clinical testing
Â· Need for new approaches to vaccine manufacturing for infectious diseases